Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Main Article Content

Richard Warren
April Armstrong
Melinda Gooderham
Bruce Strober
Diamant Thaci
Shinichi Imafuku
Howard Sofen
Lynda Spelman
Neil Korman
Min Zheng
Elizabeth Colston
John Throup
Sundeep Kundu
Renata Kisa
Subhashis Banerjee
Andrew Blauvelt

Keywords

psoriasis

Abstract

N/A

References

1. Burke JR, et al. Sci Transl Med. 2019;11:1-16.

2. Wrobleski ST, et al. J Med Chem. 2019;62:8973-8995.

3. Armstrong A, et al. Presented at the Annual Meeting of the American Academy of Dermatology; April 23-25,
2021.

4. Blauvelt A, et al. Presented at EADV 30th Congress; 29 September−2 October 2021. Poster P1391.

Similar Articles

1 2 3 4 5 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>